• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Drug delivery systems 5A. Oral drug delivery.

作者信息

Ranade V V

机构信息

Action Medical Marketing Co., Libertyville, Illinois.

出版信息

J Clin Pharmacol. 1991 Jan;31(1):2-16. doi: 10.1002/j.1552-4604.1991.tb01881.x.

DOI:10.1002/j.1552-4604.1991.tb01881.x
PMID:2045525
Abstract

The two main advantages of controlled drug delivery systems are: maintenance of therapeutically optimum drug concentrations in the plasma through zero-order release without significant fluctuations; and elimination of the need for frequent single dose administrations. The oral and other therapeutic systems in human use have validated the concept that controlled continuous drug release can minimize the daily dose of a drug required to maintain the required therapeutic effect, while minimizing unwanted pharmacological effects. By minimizing patient intervention, a design feature of therapeutic systems, compliance is automatically enhanced. Oral drug delivery systems, in particular, have required innovation in materials science to provide materials biocompatible during prolonged contact with body tissues, bioengineering to develop drug delivery modules, and clinical pharmacology for elucidation of drug action under conditions of continuous controlled drug administration. Recent work in advanced oral delivery has been primarily focused on liposome technology and the concept that substances that are normally destroyed by the stomach can be protected long enough before they could be absorbed downstream. For cost and patient convenience, oral delivery certainly would be an attractive method. The nature of biologic substances, however, with their unique technical problems, will probably limit greatly those that can be delivered orally. Besides, where delivery rate control is critical, oral delivery, even when possible, would probably be insufficiently precise. Oral delivery would also limit the substance to bloodstream delivery to the disease site. Even so, oral controlled drug delivery systems will likely find primary usefulness in specific carefully controlled therapies and prophylactic situations with due regard for drug interactions. This system represents a potentially very significant therapeutic modality. These delivery systems will find usefulness primarily in certain well-defined and well-controllable areas with due regard for individual patient variations. The purpose of the present article is to review oral controlled-release drug delivery systems, with particular emphasis on the practical aspects of testing and fabricating these systems and the underlying mechanisms by which control over drug release rate is accomplished.

摘要

相似文献

1
Drug delivery systems 5A. Oral drug delivery.
J Clin Pharmacol. 1991 Jan;31(1):2-16. doi: 10.1002/j.1552-4604.1991.tb01881.x.
2
Controlled diffusional release of dispersed solute drugs from biodegradable implants of various geometries.各种几何形状的可生物降解植入物中分散溶质药物的可控扩散释放。
Biomed Sci Instrum. 1997;33:137-42.
3
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
4
The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.硝苯地平胃肠道治疗系统(GITS)。药物、药代动力学和药理学特性评估。
Clin Pharmacokinet. 1996 Jan;30(1):28-51. doi: 10.2165/00003088-199630010-00003.
5
Controlling drug effects through improved oral formulations. The pharmacokinetics of the prazosin gastrointestinal therapeutic system.通过改进口服制剂来控制药物效果。哌唑嗪胃肠治疗系统的药代动力学。
Am J Med. 1989 Aug 16;87(2A):31S-35S. doi: 10.1016/0002-9343(89)90111-3.
6
Novel oral drug formulations. Their potential in modulating adverse effects.新型口服药物制剂。它们在调节不良反应方面的潜力。
Drug Saf. 1994 Mar;10(3):233-66. doi: 10.2165/00002018-199410030-00005.
7
Gastrointestinal dynamics and pharmacology for the optimum design of controlled-release oral dosage forms.用于控释口服剂型优化设计的胃肠动力学与药理学。
Crit Rev Ther Drug Carrier Syst. 1988;4(3):221-63.
8
Gastric retentive drug-delivery systems.胃滞留型药物递送系统
Crit Rev Ther Drug Carrier Syst. 1998;15(3):243-84.
9
An insight to osmotic drug delivery.渗透药物递送的深入了解。
Curr Drug Deliv. 2012 May;9(3):285-96. doi: 10.2174/156720112800389106.
10
Oral controlled release dosage forms. A review.口服控释剂型。综述。
Pharm Weekbl Sci. 1984 Apr 27;6(2):57-67. doi: 10.1007/BF01953956.

引用本文的文献

1
Nanomaterial-based encapsulation of biochemicals for targeted sepsis therapy.基于纳米材料的生化物质封装用于靶向性脓毒症治疗。
Mater Today Bio. 2025 Jul 4;33:102054. doi: 10.1016/j.mtbio.2025.102054. eCollection 2025 Aug.
2
A Comprehensive Review of Challenges in Oral Drug Delivery Systems and Recent Advancements in Innovative Design Strategies.口服给药系统中的挑战及创新设计策略的最新进展综述
Curr Pharm Des. 2025;31(5):360-376. doi: 10.2174/0113816128338560240923073357.
3
Rapid Sublingual Delivery of Piroxicam from Electrospun Cyclodextrin Inclusion Complex Nanofibers.
吡罗昔康从电纺环糊精包合物纳米纤维中的快速舌下给药
ACS Omega. 2022 Sep 19;7(39):35083-35091. doi: 10.1021/acsomega.2c03987. eCollection 2022 Oct 4.
4
Drug Release Profiles and Disintegration Properties of Pectin Films.果胶膜的药物释放曲线和崩解特性
Materials (Basel). 2019 Jan 24;12(3):355. doi: 10.3390/ma12030355.
5
Association between Total Daily Doses with duration of hospitalization among readmitted patients in a multi-ethnic Asian population.亚洲多民族人群再次入院患者的每日总剂量与住院时长之间的关联。
Saudi Pharm J. 2015 Sep;23(4):388-96. doi: 10.1016/j.jsps.2015.01.013. Epub 2015 Jan 10.
6
High-amylose sodium carboxymethyl starch matrices: development and characterization of tramadol hydrochloride sustained-release tablets for oral administration.高直链羧甲基淀粉钠基质:盐酸曲马多口服缓释片的研制与表征
ISRN Pharm. 2014 Apr 8;2014:391523. doi: 10.1155/2014/391523. eCollection 2014.
7
Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats.口服 VMAT2 抑制剂 GZ-793A 可减少大鼠的 methamphetamine 自我给药。
Pharmacol Biochem Behav. 2013 Nov;112:29-33. doi: 10.1016/j.pbb.2013.09.006. Epub 2013 Sep 26.
8
Controlled release drugs in overdose. Clinical considerations.过量服用的控释药物。临床考量。
Drug Saf. 1995 Jan;12(1):73-84. doi: 10.2165/00002018-199512010-00006.